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ABSTRACT Antibodies to Plasmodium falciparum are speciﬁc biomarkers that can
be used to monitor parasite exposure over broader time frames than microscopy,
rapid diagnostic tests, or molecular assays. Consequently, seroprevalence surveys can
assist with monitoring the impact of malaria control interventions, particularly in the
ﬁnal stages of elimination, when parasite incidence is low. The protein array format
to measure antibodies to diverse P. falciparum antigens requires only small sample
volumes and is high throughput, permitting the monitoring of malaria transmission
on large spatial and temporal scales. We expanded the use of a protein microarray
to assess malaria transmission in settings beyond those with a low malaria incidence. Antibody responses in children and adults were proﬁled, using a P. falciparum protein microarray, through community-based surveys in three areas in Zambia and Zimbabwe at different stages of malaria control and elimination. These three
epidemiological settings had distinct serological proﬁles reﬂective of their malaria
transmission histories. While there was little correlation between transmission intensity and antibody signals (magnitude or breadth) in adults, there was a clear correlation in children younger than 5 years of age. Antibodies in adults appeared to be
durable even in the absence of signiﬁcant recent transmission, whereas antibodies
in children provided a more accurate picture of recent levels of transmission intensity. Seroprevalence studies in children could provide a valuable marker of progress
toward malaria elimination.
IMPORTANCE As malaria approaches elimination in many areas of the world, moni-

toring the effect of control measures becomes more important but challenging.
Low-level infections may go undetected by conventional tests that depend on parasitemia, particularly in immune individuals, who typically show no symptoms of malaria. In contrast, antibodies persist after parasitemia and may provide a more accurate picture of recent exposure. Only a few parasite antigens—mainly vaccine
candidates— have been evaluated in seroepidemiological studies. We examined antibody responses to 500 different malaria proteins in blood samples collected through
community-based surveillance from areas with low, medium, and high malaria transmission intensities. The breadth of the antibody responses in adults was broad in all
three settings and was a poor correlate of recent exposure. In contrast, children represented a better sentinel population for monitoring recent malaria transmission.
These data will help inform the use of multiplex serology for malaria surveillance.
March/April 2019 Volume 4 Issue 2 e00061-19
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A

ccurate measurement of the burden of malaria and monitoring of the effectiveness
of interventions are essential for effective malaria control and elimination programs. Current methods measure the disease incidence or parasite prevalence in
children or deﬁned populations using microscopy, rapid diagnostic tests (RDTs), or
molecular methods through passive or active case detection (1). Although these
methods are useful, they typically provide prevalence estimates over a narrow window
of time, unless they are repeated frequently, and may be imprecise in areas with low
or changing transmission (2). Serology is an alternative tool for malaria surveillance and
provides a measure of parasite exposure over broader time frames than standard
diagnostic tests (3), although the patterns, breadth, and duration of parasite antigenspeciﬁc antibodies in different transmission settings are not well characterized. Serological surveys have been used to identify spatial heterogeneities in malaria transmission (4–7), monitor the impact of malaria control interventions (8), and characterize
malaria transmission intensity (3, 9). Despite its wide application, the choice of antigens
for malaria serological surveys has been restricted to vaccine candidates, such as apical
membrane antigen 1 (AMA-1), merozoite surface protein 1 (MSP1), or MSP2. These
antigens were identiﬁed in searches of antigens that induce protective immunity and
may not necessarily be good candidates to measure the history of exposure to malaria
parasites. The protein microarray is a highly versatile and high-throughput platform to
study protein interactions, including, but not limited to, proﬁling of the serological
responses following infection by pathogens of interest. Many studies have used protein
microarrays to identify antibody signatures associated with protective immunity to
Plasmodium falciparum infection (10–16). However, the application of protein microarray data for disease surveillance is in its infancy (17).
To identify the serological proﬁles associated with different malaria transmission
settings, a protein array platform in which expressed proteins are printed onto a
support surface was used to measure antibodies to 500 P. falciparum antigens in
samples collected in community-based surveys in three transmission settings in Zambia
and Zimbabwe: (i) Choma District in Southern Province, Zambia (18), which underwent
a dramatic decline in malaria transmission over the past decade and where malaria is
nearing elimination; (ii) Nchelenge District in Luapula Province in northern Zambia (18),
which has had high, perennial transmission, despite the use of malaria control measures, such as insecticide-treated bed net distribution and focal indoor residual spray
(IRS) campaigns; and (iii) Mutasa District in eastern Zimbabwe (18, 19), which borders
Mozambique and which experienced a malaria resurgence after successful malaria
control, although recent IRS campaigns with pirimiphos-methyl have successfully
reduced the malaria burden (20) (Fig. 1). The serological proﬁles among children and
adults in these different ecological and geographical settings reﬂect the malaria
transmission histories and inform progress toward control and elimination.
RESULTS
Characteristics of study population. A total of 429 samples were collected in
serial, cross-sectional, community-based surveys from 290 individuals from 3 sites in
2015. Data from 213 individuals were analyzed (Table 1). In the low-transmission setting
in Choma District, Zambia, 70 samples from 70 individuals were analyzed. In the
intermediate-transmission setting in Mutasa District, Zimbabwe, 156 samples from 78
individuals were analyzed, and in the high-transmission setting in Nchelenge District,
Zambia, 124 samples from 69 individuals were analyzed. The age of the participants
ranged from younger than 1 year to 86 years, with the median age per site ranging
from 15 to 21 years. Fever (tympanic temperature, ⱖ38°C) on the day of screening was
rare among this population across all the transmission intensity levels, indicating that
most infected individuals were asymptomatic. As not all residents were home at the
March/April 2019 Volume 4 Issue 2 e00061-19
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FIG 1 Trends in malaria burden in the three study sites and timing of sample collection for serological studies. (A to C) Charts showing trends in malaria burden
over a 6-year period for Choma District, Zambia, with successful malaria control (entomological inoculation rate, ⬍1; prevalence, 1%) (A), Mutasa District,
Zimbabwe, with resurgent malaria after previous control, followed by decreasing transmission after indoor residual spraying (entomological inoculation rate,
10; parasite prevalence, 5 to 10%) (B), and Nchelenge District, Zambia, with ineffective malaria control (entomological inoculation rate, 80; parasite prevalence,
50%) (C). The timing of sample collection for the serological assays is indicated by linked dots. (D) A map of South Africa shows the location of the study sites.
nd, not done.

time of the study visit, the number of visits per participant varied. Samples collected
from 13 adults in Choma District, Zambia (median age at the ﬁrst visit, 57 years) from
5 time points spanning June 2013 to June 2015 were also analyzed. In addition to the
samples collected from community surveys, samples from 35 RDT-positive, symptomatic patients attending rural health centers in the Macha Hospital catchment area in
Choma District, Zambia, were analyzed (Table 1).
Overall serological proﬁles in different malaria transmission settings. Of the
500 P. falciparum antigens on the array, the number of antigens recognized in individual participants (breadth of the antibody proﬁle) was highly variable, ranging from less
than 10 to more than 300 antigens, depending on the age of the participants and the
sites where the samples were collected. Overall, 129 antigens were above the seropositivity threshold (log2 fold change in expression over that for the control, i.e., fold over
control [FOC], ⬎1) based on the mean signal for the whole study population. Shown in
Fig. 2 are the average signal intensities against these 129 seropositive antigens for
children (age range, 0 to 5 years) and adults (age, ⬎20 years) in each site. The greatest
difference between children and adults was in the low-transmission setting in Choma
District (Fig. 2A), whereas the lowest difference was in the high-transmission setting in
March/April 2019 Volume 4 Issue 2 e00061-19
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not applicable.

Near elimination
70
51
17 (6–47)
70
0
0
0

Malaria transmission
No. of participants
% male participants
Median (interquartile range) age (yr) at ﬁrst visit
No. of plasma samples
% of participants febrile on day of screening
% of participants microscopy positive
% of participants RDT positive

aNA,

Choma District,
Zambia
Jun 2015

Characteristic
Sampling date(s)
Intermediate
78
46
15 (6–33)
156
0.4
Apr, 1.3; Aug, 1.3
Apr, 2.6; Aug, 1.3

Mutasa District,
Zimbabwe
Apr and Aug 2015

Serial cross-sectional survey

Active community surveillance

Value for the indicated location:

TABLE 1 Characteristics of study sites and participants

High
69
45
21 (9–39)
124
1.7
Apr, 27; Jun, 25; Aug, 21
Apr, 36; Jun, 43; Aug, 27

Nchlelenge District,
Zambia
Apr, Jun, and Aug 2015

Choma District, Zambia,
complete follow-up for 2 yr
Jun and Dec 2013, Jun and
Dec 2014, Jun 2015
Near elimination
13
54
57 (44–68)
65
0
0
0

Near elimination
35
63
11 (4.4–33)
35
84
NAa
100

Clinical samples from
Choma District, Zambia
Nov 2013 to May 2015
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FIG 2 Comparison of Plasmodium falciparum-speciﬁc seropositive antigen responses in adults and children. Antibody responses in adults
(⬎20 years old) and children (0 to 5 years old) are arranged from left to right according to the average signal intensity across the three sites. A
cutoff log2 FOC of 1 was used to deﬁne seropositivity. The antigens are listed in the same order in each panel. Of 500 P. falciparum antigens on
the array, 129 antigens were seropositive. Benjamini-Hochberg (BH)-corrected P values for t tests comparing adults and children are shown
(secondary y axis), and the cutoff value for signiﬁcance (P ⬍ 0.05) is indicated.

Nchelenge District (Fig. 2C). Mutasa District showed an intermediate picture (Fig. 2B).
Similarly, the number of exon products that were differentially recognized (BenjaminiHochberg [BH]-corrected P value [P_BH] ⬍ 0.05) by children and adults was 97, 100, and
1 in the Choma District, Mutasa District, and Nchelenge District, respectively (data not
shown).
Unsupervised principal-component analyses (PCA) of the proﬁles in children separated the three sites from each other and from U.S. naive controls (Fig. 3A), consistent
with the different transmission intensities across the three sites. Despite adults having
broader and more overlapping proﬁles than children, the adult proﬁles also resolved
into distinct clusters according to transmission intensity (Fig. 3B), possibly reﬂecting a
geographical component to the antibody signature. This hypothesis was supported by
hierarchical clustering of data for all 500 exon products on the array (see Fig. S1 in the
supplemental material). In children, samples from Nchelenge District, Zambia, and
Choma District, Zambia, clustered together on the same major limb of the dendrogram,
despite having the highest and lowest signals, respectively, while samples from Mutasa
District, Zimbabwe, clustered in a separate limb.
Magnitude of age-speciﬁc serological proﬁles for the top 30 antigens in different malaria transmission settings. We then examined the responses to the
dominant antigens, deﬁned by ranking all 500 P. falciparum antigens on the array by
the average ﬂuorescence signal in descending order. The top 30 dominant antigens
(listed in Table S1) included six P. falciparum EMP1 (PfEMP1) exon products mapping to
the conserved intracellular domain, ﬁve merozoite surface proteins (MSP1, -2, -4, -10,
and -11), three early transcribed membrane proteins (ETRAMP2, -5, and -14), and two
liver-stage antigens (LSA1 and -2).
March/April 2019 Volume 4 Issue 2 e00061-19
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FIG 3 Unsupervised principal-component analysis (PCA) of 129 seroreactive antigens for adults and children from different geographical locations. (A) Children
(0 to 5 years old); (B) adults (⬎20 years old). Samples are color coded in accordance with the geographical location, as indicated on the plot.

Scatter plots of the average signal intensity of the top 30 antigens for the 3 settings,
as well as signals from adults from the United States (a nontransmission setting) and
adults from Papua New Guinea (PNG; a high-transmission setting) (Fig. 4), revealed ageand transmission intensity-dependent patterns similar to those achieved with all 129
seropositive antigens. In the low-transmission setting in Choma District, Zambia, the
signals were the lowest in children younger than 5 years of age. None had an average
log2 FOC above the cutoff of 1, and the signals were similar in magnitude to the
corresponding antibody signals in healthy U.S. adults (Fig. 4A and D, respectively),
reﬂecting the low transmission in Choma District. The antibody signal intensity increased with increasing age, with 81% of adults in Choma District older than 20 years
of age seropositive for the highest-intensity 30 antigens. These may represent the
durable antibody responses generated when transmission was higher in this location.
In the resurgent malaria transmission setting in Mutasa District, Zimbabwe, antibody
signals for the highest-intensity 30 antigens also increased with age (Fig. 4B) but were
higher than those in the low-transmission setting in Choma District, Zambia, particularly among children and adolescents. Thirty-seven percent of children younger than 5
years of age and 83% of adults older than 20 years of age were seropositive for the
highest-intensity 30 antigens.
In the high-transmission setting in Nchelenge District, Zambia, antibody signals
were high across all ages, with all participants, including children younger than 5 years
of age, being seropositive for the highest-intensity 30 antigens (Fig. 4C). These signals
were comparable in magnitude to those of samples from PNG.
Breadth of antigen-speciﬁc antibody responses by age in different malaria
transmission settings. The results of analysis of the antibody responses to the
individual top 30 antigens are shown in Fig. S2. These mirrored the average signal data
March/April 2019 Volume 4 Issue 2 e00061-19
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FIG 4 Age-stratiﬁed protein microarray data for different transmission settings. (A to C) Scatter plots of
the mean signal intensity for the 30 antigens with the highest antibody signal intensities (log2 FOC) by
age for each transmission setting. Individual symbols represent single serum samples. Samples from
RDT-negative and -positive samples are indicated by solid and open symbols, respectively. The RDTpositive samples are colored red and green to distinguish, respectively, active community surveillance
samples from samples from patients with malaria presenting to rural health centers in the Macha
Hospital catchment area in Choma District. (A) Choma District, Zambia, samples collected from June 2015
(n ⫽ 70 community surveillance donors, 70 samples, plus n ⫽ 35 care-seeking individuals, 35 samples).
(B) Mutasa District, Zimbabwe, samples collected from April and August 2015 (n ⫽ 78 donors, 156
samples). (C) Nchelenge District, Zambia, samples collected in April, June, and August 2015 (n ⫽ 69
donors, 124 samples). Hashed lines signify children (0 to 5 years) and adults (⬎20 years), with the
percentage of RDT-negative samples in each age group above a cutoff of a log2 FOC of ⬎1 being shown
at the top of each panel. (D) Healthy U.S. adults (n ⫽ 14). (E) Healthy adults from Papua New Guinea
(n ⫽ 5). The top 30 antigens are listed in Table S1 in the supplemental material.

described above and further highlight age-speciﬁc differences in the breadth of the
antibody responses in different transmission settings. In the low-transmission setting in
Choma District, Zambia, children younger than 5 years of age not only had the lowest
antibody signal intensities but also had the narrowest antibody proﬁles, being seropositive for only 5 of 500 P. falciparum antigens (Fig. S2). The antibody breadth
increased 5-fold in children 6 to 10 years of age (seropositive to 25 antigens) and
15-fold in individuals 11 to 20 years of age. Adults between 20 and 40 years of age were
seropositive to 153 of 500 antigens. In the intermediate-malaria-transmission setting in
Mutasa District, Zimbabwe, the antigen-speciﬁc antibody signal intensity similarly
increased with age, but the breadth of the antibody response was greater in each age
group in this setting than in the low-transmission setting. Speciﬁcally, children younger
than 5 years of age were seropositive to 15 antigens and children 6 to 10 years of age
were seropositive to 53 antigens. In contrast to the low- and intermediate-transmission
sites, the acquisition of antigen-speciﬁc antibodies in Nchelenge District, Zambia, was
rapid. Children younger than 5 years of age had antigen-speciﬁc antibody proﬁles that
were approximately 80% of those of adults.
Magnitude of antibody signals associated with parasitemia. It was of interest to
determine the effect of infection with P. falciparum on the magnitude of antibody
signals and the breadth of antibody proﬁles. Therefore, we compared RDT-positive and
-negative samples for the 3 sites (open and ﬁlled symbols in Fig. 4, respectively). For
March/April 2019 Volume 4 Issue 2 e00061-19
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TABLE 2 Antigens differentially recognized by RDT-negative and RDT-positive participants from Choma District, Zambiaa
PF3D7 gene
identiﬁer
0532100
0800200
0220000
1007700
0223300
1300300
0315400
0903500
1222600
1033200
1121800
1301400
0817300
1353100
0711700
0808600
0301700
1109200
0202000

SI for the following participants:
Exon
Exon 2, segment 1
Exon 2, segment 2
Exon 1, segment 2
Segment 2
Exon 1 of 1
Exon 1, segment 1
Exon 1, segment
Segment 1
Exon 2 of 2
Exon 1, segment
Exon 2, segment
Exon 2, segment
Exon 2, segment
Exon 2, segment
Exon 3 of 4
Exon 2, segment

1

3
1
1
1
1
1

Name
ETRAMP5
PfEMP1
LSA3
ApiAP2
PfEMP1
PfEMP1
Unknown function
Unknown function
ApiAP2
ETRAMP10.2
Peptidase, M16 family
Hyp12, unknown function
Asparagine-rich antigen
Exported protein, unknown function
PfEMP1
PfEMP1
Exported protein, unknown function
Conserved protein, unknown function
KAHRP

RDT negative (n ⴝ 30)
0.86
0.39
0.58
0.47
0.47
0.52
0.60
0.37
0.54
0.35
0.64
0.49
0.38
0.10
-0.23
0.17
0.29
0.38
0.24

RDT positive (n ⴝ 12)
2.17
2.07
1.98
1.95
1.88
1.85
1.79
1.71
1.61
1.58
1.43
1.36
1.35
1.27
1.27
1.20
1.18
1.15
1.07

P_BH
0.0169
0.0169
0.0140
0.0428
0.0169
0.0140
0.0169
0.0140
0.0169
0.0140
0.0241
0.0367
0.0169
0.0140
0.0169
0.0394
0.0169
0.0367
0.0140

aSI,

signal intensity (log2 FOC); RDT, rapid diagnostic test; P_BH, Benjamini-Hochberg [BH]-corrected P value (P value corrected for false discovery); ETRAMP, early
transcribed membrane protein; LSA, liver-stage antigen; PfEMP, P. falciparum erythrocyte membrane protein; ApiAP2, transcription factor with an AP2 domain(s);
KAHRP, knob-associated histidine-rich protein. Data are shown in Fig. S3 in the supplemental material

Choma District, since none of the community surveillance participants were RDT
positive, Fig. 4 shows the signals for 35 RDT-positive malaria cases (age range, 2 to 78
years; median age, 11 years) attending health care facilities in the catchment area of
Macha Hospital, Choma District. In Mutasa District, 0.9 to 4.1% and 27% to 43% of
Nchelenge District participants were RDT positive, depending on the time of sample
collection (Table 1). Overall, RDT-positive individuals had elevated antibody signals
relative to age-matched RDT-negative individuals in all three sites, consistent with the
ﬁndings of similar studies performed elsewhere (21–24). The differential was the
greatest in individuals in Choma District, particularly in children, where the background
seroreactivity was the lowest. Thus, for children aged 0 to 10 years, parasitemia was
associated with elevated antibody signals on the array, with a mean log2 FOC of 0.41
for RDT-negative individuals (n ⫽ 30) and 1.44 for RDT-positive individuals (n ⫽ 12). In
this age group there was also an increase in the breadth of the antibody proﬁles
associated with parasitemia, ranging from 9 to 57 seropositive antigens (Fig. S3). Of the
57 seropositive antigens recognized by RDT-positive participants, 19 were differentially
recognized (P_BH ⬍ 0.05) between those who were RDT positive and those who were
RDT negative (listed in Table 2) and could be potential serodiagnostic antigens. In
Nchelenge District, the differential between the RDT-positive and -negative participants
was marginal (mean log2 FOC ⫽ 3.1 and 3.2, respectively) owing to the elevated signals
found in RDT-negative individuals.
Children younger than 5 years of age as a sentinel surveillance population. The
utility of children younger than 5 years of age as a sentinel surveillance population for
serological monitoring of ongoing malaria transmission and documentation of elimination was tested by comparing the signals to the top 30 antigens in children and
adults across the three transmission settings and in the U.S. and PNG controls (Fig. 5;
Table S2). The signals from children in Choma District and U.S. adults were not
signiﬁcantly different, consistent with the low transmission in Choma District. Although
children in Mutasa District had a higher median signal to the top 30 antigens than
children in Choma District, consistent with reemergence in Mutasa District prior to the
recent decline, the difference was not signiﬁcant.
The signals from children from Choma and Mutasa Districts were highly signiﬁcantly
different from those from children in Nchelenge District, consistent with the higher
transmission in the latter setting. Unlike the signals from children, signals from adults
March/April 2019 Volume 4 Issue 2 e00061-19

msphere.asm.org 8

Antibody Signatures and Malaria Control in S. Africa

FIG 5 Comparisons of antibody signal intensities for the top 30 antigens between children and adults. Box
plots of antibody signal intensities for the top 30 antigens that gave the highest antibody signal intensities
across the three transmission settings, as well as for U.S. healthy controls (US; adults) and individuals from
a high-transmission setting in Papua New Guinea (PNG; adults). P values for nonparametric comparisons
were adjusted using Dunn’s correction. All possible pairwise comparisons are listed in Table S2 in the
supplemental material. The number of seropositive antigens out of 500 on the P. falciparum array above a
cutoff of log2 FOC ⬎1 is shown at the top of each plot.

were less discriminatory, with the distribution of the average signals for the top 30
antigens being indistinguishable between Choma and Mutasa Districts. The signals
from adults in both districts were signiﬁcantly lower than those from adults in Nchelenge District. Antigen-speciﬁc antibody signal intensities among adults in the hightransmission setting in Nchelenge District, Zambia, were not signiﬁcantly different from
those in a high-transmission reference sample from PNG. Antigen-speciﬁc antibody
signal intensities among adults in the low-transmission setting in Choma District,
Zambia, and the intermediate-transmission setting in Mutasa District, Zimbabwe, were
lower than those in the high-transmission setting but higher than those in U.S. adults.
With the aim of achieving improved discrimination between children in low- and
intermediate-transmission settings (Choma District and Mutasa District, respectively),
signals for individual top 30 antigens were compared using both t tests and receiver
operating characteristic (ROC) analyses (Fig. S4). A number of discriminatory antigens
produced signiﬁcantly higher signals in children from Mutasa District than in children
from Choma District. Four of these yielded area-under-the-ROC-curve (AUC) values of
⬎0.9; speciﬁcally, these were ApiAP2 (0.976), PfEMP1 (0.963), SERA4 (0.919), and a
protein of unknown identity (PF3D7_0903500). Further experiments using puriﬁed
protein antigens in other immunoassay formats, such as enzyme immunoassays, would
be needed to validate these as potential serodiagnostic antigens for recent exposure.
Antibodies persist after reduction of malaria transmission. The prevalence of
antibodies to P. falciparum in adults in Choma District, Zambia, following a dramatic
decline in malaria transmission over the past decade suggests long-term antibody
March/April 2019 Volume 4 Issue 2 e00061-19
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FIG 6 Persistent antibody responses among adults in Choma District, Zambia, to the 30 antigens (Ags) with the highest
antibody signals. Mean antibody signal intensities for the 30 antigens with the highest antibody signal intensities are shown
for ﬁve time points over 2 years in 13 adults (age range, 35 to 82 years; median age, 60 years) residing in the low-transmission
setting in Choma District, Zambia. Slope refers to the slope of the regression line through the 5 time points for each antigen.
For comparison, mean antibody signal intensities for the same top 30 antigens are shown for children (age, 0 to 5 years) and
adults (age, ⬎20 years) residing in the high-transmission setting of Nchelenge District, Zambia. Individual antigens are
represented by different symbols. The number of seropositive antigens out of 500 on the P. falciparum array above a cutoff
of a log2 FOC of ⬎1 is shown at the top of each plot.

persistence. This was conﬁrmed by measuring antibody responses to the 30 antigens
with the highest signal intensity in a cohort of 13 adults from Choma District, Zambia,
from whom samples were assayed at ﬁve time points between June 2013 and June
2015 (Fig. 6). The magnitude of the responses to the 30 antigens with the highest signal
intensity was stable during the 2-year period, as was the breadth of the antibody
proﬁle. However, slopes for 26 of the 30 antigens were negative (data not shown),
consistent with some waning of antibody levels.
Validation of diagnostic antigens. Analysis of the data using the two-component
mixture model generated a list of 30 dominant antigens (Table S1), of which 27 were
also on the top 30 antigen list using the FOC method. This provides a useful crossvalidation using two independent analytical methods. One of the goals of this study
was to identify and validate potentially useful biomarkers for monitoring recent exposure to P. falciparum. Several reactive antigens identiﬁed among corresponding in vitro
transcription/translation (IVTT)-expressed exon products were also represented by
Escherichia coli-derived puriﬁed proteins on the same array (Table S3), namely, EBA175,
MSP1, MSP2, LSA1, and CSP. Scatter plots of array signal intensity data for puriﬁed
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protein versus an IVTT-expressed exon product(s) were generated (Fig. S5). Good
correlations were seen for MSP2 (R2 ⫽ 0.89) and EBA175 (R2 ⫽ 0.75), and modest
correlations were seen for CSP (R2 ⫽ 0.6), LSA1 (R2 ⫽ 0.57), and MSP1 (R2 ⫽ 0.58 for IVTT
segment 2 and R2 ⫽ 0.47 for IVTT segment 1). The highest correlation was seen for
MSP2, where both the IVTT and puriﬁed versions were full-length proteins. Full-length
PfCSP was also represented as an IVTT protein and a puriﬁed protein, although the
reactivity to the puriﬁed protein was considerably higher than that to the IVTT protein,
with a correspondingly lower correlation. This may reﬂect the low expression levels of
this particular protein in the IVTT system. EBA175 also gave relatively good correlations,
despite the different lengths of proteins used. Thus, for IVTT expression, exon 1
(4,263 bp) was ampliﬁed and expressed as two half-size segments (segments S1 and S2)
and printed separately. Shown in Fig. S5 is the correlation of the antibody signals
obtained using IVTT-expressed S2 (corresponding to residues 702 to 1421) and puriﬁed
EBA175 conserved regions RIII to RV (25, 26), corresponding to residues 761 to 1298
(27). The IVTT expression product overlapped the entire RIII to RV puriﬁed protein
fragment, and any discrepancies in the correlation may be accounted for by the
additional 59 and 123 amino acids at the N- and C-terminal ends of the IVTT expression
product, respectively, that may provide epitopes for antibody recognition that are
absent from the RIII to RV fragment. MSP1 gave weak correlations. For IVTT expression,
the single exon of MSP1 (5,163 bp) was ampliﬁed in two segments (segments S1 and
S2) corresponding to the N- and C-terminal 870 and 868 residues, respectively, and
printed separately. Figure S5 shows the correlation obtained using IVTT-expressed
segment S1 or S2 compared to puriﬁed MSP1-19 (corresponding to residues 1607 to
1702 of MSP1) glutathione S-transferase fusion protein. Segment S1 and MSP1-19 do
not overlap, which presumably accounts for the weakest correlation seen in Fig. S5.
Although segment S2 completely overlaps MSP1-19, the IVTT exon product has an
additional ⬃770 residues that may provide epitopes for antibody recognition that are
absent from the MSP1-19 fragment. Finally, for IVTT expression of LSA1, the single exon
(3,489 bp, 1,162 amino acids) was ampliﬁed in two segments. Segment 1 of 2 contains
the N-terminal 250 residues. Figure S5 shows the correlations of the antibody signals
obtained using IVTT segment 1 and the puriﬁed LSA-NRC vaccine antigen, which
comprises the N- and C-terminal regions of LSA1 (residues 28 to 154 and 1630 to 1909)
with two 17-amino-acid repeats located between (28). The correlation between IVTT
protein and puriﬁed protein was weak, presumably because the IVTT expression
product lacks the C-terminal region that may provide additional epitopes for antibody
recognition that are absent from the IVTT-expressed segment. Given that many of the
IVTT-expressed versions were exon products and not full-length proteins, strong correlations are not expected for all antigens.
Additional validation using puriﬁed proteins, preferably of equivalent length, is
needed. Nevertheless, these arrayed puriﬁed proteins also reﬂected the same age- and
transmission intensity-dependent patterns seen with the average top 30 IVTT expression exon products (Fig. S6). Thus, all ﬁve antigens revealed signiﬁcantly higher signals
in children from Nchelenge District than in children from Choma District and Mutasa
District, while signals in adults in Nchelenge District were not signiﬁcantly higher than
those in adults at the other two sites.
DISCUSSION
A protein array platform was used to characterize age-speciﬁc serological proﬁles
and the breadth of antibody responses to 500 P. falciparum antigens in three transmission settings in Zambia and Zimbabwe. Based on the 30 antigens with the highest
signal intensity, distinct age-speciﬁc patterns that reﬂected recent and past P. falciparum transmission levels were identiﬁed. Thus, young children in the low-transmission
setting of Choma District, Zambia, had antibodies to the fewest P. falciparum antigens.
This reﬂected the recent decline in malaria transmission and the sustained low malaria
transmission and could lead to methods to document progress toward elimination. By
comparison, adults in the low-transmission setting had high antibody signals, which
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persisted for the 2 years of a longitudinal study, highlighting their durability. We
speculate that these are a legacy of the hyperendemic malaria that existed in this area
over a decade ago but could reﬂect periodic exposure to P. falciparum in the absence
of clinical disease. Asymptomatic and low-parasitemic infection occurs even in the
setting of declining malaria transmission in Choma District, Zambia. Community-based
epidemiological surveillance studies reported a low but persistent parasite prevalence
in the population (29, 30). Both studies reported that approximately half of individuals
with parasitemia by PCR had insufﬁcient parasite levels to be detected by RDTs
(subpatent infection) and that most were asymptomatic. Persistent antibody levels in
adults from Choma District may therefore reﬂect more recent subpatent infection.
Interestingly, adults in the resurgent setting of Mutasa District, Zimbabwe, had lower
antibody signals and breadth than similarly aged individuals in Choma District, Zambia,
again, likely reﬂecting higher levels of malaria transmission in Choma District, Zambia,
more than a decade ago. In contrast, in the high-transmission setting of Nchelenge
District of Zambia, the antibody signal intensities for children younger than 5 years of
age resembled those for adults from the same setting, reﬂecting the persistent high
transmission.
Numerous studies have characterized serological responses to P. falciparum antigens in sub-Saharan Africa, but none have measured antibodies to 500 P. falciparum
proteins across such divergent transmission settings using the same protein array
platform. Recently, serological studies measuring antibody responses to malaria vaccine
candidates, such as apical membrane antigen 1 (AMA-1) and merozoite surface protein
1 (MSP1) blood-stage antigen, were used to identify the spatial heterogeneity in malaria
transmission that could be used to target malaria interventions (31). In a preelimination
setting in Swaziland, where only 2 individuals among 4,330 participants were found to
be parasitemic by PCR, pooled PCR and serology were shown to be valuable surveillance tools (32). Seropositivity to AMA-1 and MSP142 were associated with age older
than 20 years and recent travel to Mozambique (32). Across different transmission
settings in Uganda, serological responses to AMA-1 were a better metric of transmission
intensity than anemia or parasitemia (33).
The full breadth of reactive antigens in malaria was not fully appreciated until
proteome-wide screening techniques, such as the multiplex microarray, were introduced (34–36). The array revealed many novel antigens with potential diagnostic and
vaccine applications (11, 14, 21, 37, 38). The array format is also high throughput and
inherently sample sparing, yet the real strength in the multiplex format lies in the
collective proﬁle of the reactive antigens that it generates, which frequently allows for
discrimination between patient groups, such as children with and without clinical
immunity (11, 15), or recent and past exposure (17), superior to that which can be
achieved from individual antigens alone. Measurement of antibodies to 500 P. falciparum proteins across divergent transmission settings using the same protein array
platform provides a collective proﬁle of reactive antigens. The dominance of antibodies
to blood-stage antigens is consistent with the ﬁndings of other antibody proﬁling
studies of naturally acquired immunity to P. falciparum in Africa (22, 23).
Age-speciﬁc seroprevalence proﬁles can be a useful marker of declining malaria
transmission, as was shown in the Gambia and Guinea-Bissau (39), and seroprevalence
in young children serves as the best indicator of recent malaria transmission. In our
low-transmission setting in Choma District, Zambia, where malaria transmission has
declined over the past decade, none of the study participants younger than 5 years of
age were seropositive, whereas 81% of adults were seropositive, reﬂecting the recent
changes in malaria transmission. Other studies in sub-Saharan Africa have similarly
demonstrated the value of serosurveillance in young children. For example, declining
malaria transmission in the Gambia was captured by detection of a decline in seroprevalence in children 1 to 5 years of age (40).
One limitation of this analysis is the focus on antibody responses to the 30 antigens
with the highest signal intensity, perhaps selecting for antibodies with longer half-lives
and obscuring important but less intense antibody responses with more variable decay
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kinetics. Among adults residing in the low-transmission setting in Choma District,
Zambia, antibodies to the 30 antigens with the highest signal intensity persisted long
after the decline in malaria transmission over the past decade. In contrast, of the 14 P.
falciparum antigens with short-lived antibody responses identiﬁed as markers of recent
exposure in Ugandan children (17), 6 were represented among the 30 antigens with the
highest signal intensity. The identiﬁcation of antibodies to P. falciparum antigens with
rapid decay kinetics may assist in the detection of recent exposure in preelimination
settings. We previously measured serological responses to whole-parasite lysate in the
low-transmission setting in Choma District, Zambia, and described increasing seroprevalence with age as well as a spatial overlap between areas of seropositivity and
malaria risk based on parasite prevalence (41).
Multiplex serology is a more sensitive measure of exposure than other methods that
depend on the presence of parasites (22, 23). There is an extensive literature on the use
of serology for surveillance in malaria (42, 43), and wider use of the protein microarray
technology to leverage these advantages will require a solution more deployable than
conventional confocal laser scanners. To this end, we recently validated a portable
digital complementary metal oxide semiconductor (CMOS) array imaging system as a
low-cost and robust alternative that could easily be deployed in laboratory settings
where the purchase and maintenance of a more complex machine would be cost
prohibitive or impractical (44). We also reported that the probing protocol was readily
translated to other labs, as shown by excellent correlations between the data generated
by ﬁve independent laboratories (45). With the availability of training and commercial
sources of arrays, the microarray technology can be disseminated more widely, particularly in areas of endemicity, where it will have the greatest impact on public health.
In summary, we showed that protein arrays permit measurement of antibody
responses to hundreds of parasite antigens to identify antigen-speciﬁc antibody responses in different transmission settings and with different decay kinetics. Using
samples obtained from divergent epidemiological settings, the 500-P. falciparumprotein microarray used in this study captured distinct serological proﬁles reﬂective of
their malaria transmission histories. Furthermore, antibodies in adults persisted in the
absence of signiﬁcant recent transmission, but antibodies in children provided an
accurate picture of recent changes in transmission intensity. Seroprevalence studies in
children could be used to target malaria interventions and provide a valuable marker
of progress toward malaria elimination.
MATERIALS AND METHODS
Study sites. Figure 1 shows the locations and trends in malaria transmission over time in each of the
three study sites. Weekly rapid diagnostic test (RDT)-positive counts from local health facilities in
individuals younger than 5 years of age and over 5 years of age were reported to the Southern Africa
International Centers of Excellence in Malaria Research (ICEMR) and plotted (46–48). The low-malariatransmission site (Fig. 1A) consisted of the catchment area of the Macha Mission Hospital, a rural
settlement in Choma District, Southern Province, Zambia. The area has a tropical savannah climate with
cool (May to July) and hot (August to October) dry seasons and a single rainy season (November to April).
Malaria transmission is highest during the rainy season, with Anopheles arabiensis mosquitoes being the
primary malaria vector (19, 49). Malaria transmission in Southern Province, Zambia, has declined over the
past 15 years (19), with a parasite prevalence of approximately 1% by RDT.
The intermediate-malaria-transmission site (Fig. 1B) was Mutasa District, Manicaland Province, Zimbabwe, which lies in the mountainous area of eastern Zimbabwe bordering Mozambique. The seasonal
rains are similar to those in Zambia, and the primary malaria vector is A. funestus mosquito (50). Mutasa
District had an effective malaria control program from the early 1950s to early 1990s (47), but due to
ﬁnancial constraints, the malaria control program was halted and a resurgence of malaria occurred.
Recent annual IRS campaigns using pirimiphos-methyl that began in 2014 successfully reduced the
burden of malaria (20).
The high-malaria-transmission site (Fig. 1C) was in Nchelenge District, Luapula Province, Zambia,
which shares a border in the west with the Democratic Republic of the Congo and lies in the marshlands
of the Luapula River and Lake Mweru. The pattern of rain follows that of Southern Province, Zambia,
although the monthly precipitation in Nchelenge District is higher. A. funestus and A. gambiae mosquitoes are the major malaria vectors, and the extended marshlands provide mosquito breeding sites
throughout the year (51), resulting in perennial, holoendemic transmission. Despite intensiﬁed malaria
control efforts, including IRS campaigns with pirimiphos-methyl, malaria transmission remains high (48),
with parasite prevalence, as determined by RDT, being higher than 50% throughout the year.
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Sample and data collection. Simple and stratiﬁed random sampling was used to select households
for participation in community-based, cross-sectional, and longitudinal surveys as previously described
(2). Brieﬂy, households were randomly selected using high-resolution satellite images of the study area.
All household residents present at the time of the visit were eligible for enrollment, and written informed
consent was obtained from those who agreed to participate and from the caregivers of children.
Household visits for the serological studies took place every 6 months between June 2013 and December
2015 in Choma District, Zambia, every 2 months between February and August 2015 in Nchelenge
District, Zambia, and every 4 months between February and August 2015 in Mutasa District, Zimbabwe.
To screen for malaria at the household, a PfHRP2-based RDT (SD Bioline Malaria Ag P.f; Standard
Diagnostics Inc., Republic of Korea) was performed using blood samples collected by ﬁnger prick.
Artemether-lumefantrine was offered to treat RDT-positive male and nonpregnant female participants.
For serological testing, blood was collected by ﬁnger prick using a capillary tube (Microvette CB300;
Sarstedt, Nümbrecht, Germany) and stored on ice packs until it was transported to a local laboratory. The
blood sample was centrifuged at 14,000 rpm for 1 min to separate the plasma. Plasma samples were
stored at ⫺80°C until they were shipped to the University of California, Irvine, on dry ice, where they were
again stored at ⫺80°C until probing.
Protein microarrays. A custom protein microarray was used to measure antibody responses to P.
falciparum as described previously (34). Brieﬂy, 500 exons from P. falciparum (strain 3D7) were ampliﬁed
from genomic DNA and cloned into a T7 expression vector using homologous recombination. Each was
expressed in individual E. coli-derived in vitro transcription/translation (IVTT) reactions (5-Prime GmbH,
Hilden, Germany) and printed directly onto nitrocellulose-coated glass slides (Grace Bio-Labs Inc., Bend,
OR). In addition to the 500 exon products, each array also contained 24 IVTT control (IVTTc) reactions that
lacked expression plasmids. Also printed on the array were several puriﬁed proteins designed to provide
a useful bridge between the array platform and other assay formats that use puriﬁed antigens. These
antigens included recombinant PfCSP (a gift of Ashley Birkett, PATH) (52, 53), PfLSA1 deleted of the
internal repeat domain (a gift of David Lanar, WRAIR) (28), and PfEBA175, PfEBA140, PfMSP1, PfMSP2,
PfMSP3, PfRh2, and two long synthetic peptides of PfRh1 (all gifts of James Beeson, Burnet Institute,
Melbourne, Australia) (25). Each IVTT expression product contained N-terminal polyhistidine and
C-terminal hemagglutinin epitope tags to monitor expression for quality control.
Array probing and data acquisition were performed as described previously (54). To minimize
interexperimental variability and array print-batch effects, data were obtained by probing the samples at
the same time on the same batch of arrays. Also probed were samples from 15 healthy U.S. adult controls
and highly reactive RDT-negative sera from semi-immune adults from Papua New Guinea (PNG).
Raw data were collected as the median pixel signal intensity for each spot subtracted automatically
from the local background. Data were normalized using the formula log2[IVTT ⫺ (SM ⫺ GM)]/GM, where
IVTT is the exon product signal, SM is the median of the sample-speciﬁc IVTTc signals, and GM is the
global median of the IVTTc signals. Fold over control (FOC) normalization provides relative measures of
the speciﬁc antibody binding to the nonspeciﬁc antibody binding to the IVTT controls. Thus, with the
normalized data, a value of 0.0 means that the intensity is not different from the background intensity
and a value of 1.0 indicates a doubling with respect to the background. A threshold of a log2 FOC of 1
was used to deﬁne seropositivity.
To compare the antibody responses between groups, two metrics were used: (i) magnitude, deﬁned
as the log2 FOC for each antigen, in which antigens were ranked by the mean signal across the whole
study population and the mean for the top 30 was used for comparisons between different age groups
and settings, and (ii) the breadth of the antibody proﬁle, deﬁned as the number of seropositive antigens
(log2 FOC ⬎ 1) recognized by an individual or for a population using the mean signal intensity for the
population. Differentially reactive proteins between groups were determined using signal intensities and
a Bayes regularized t test for protein arrays (55). To account for multiple-comparison conditions, the
Benjamini and Hochberg (BH) method was used to control the false discovery rate to give corrected P
values (P_BH) (56); a P_BH of ⬍0.05 was considered signiﬁcant. Receiver operating characteristic (ROC)
analyses and the area under the ROC curve (AUC) were determined using the R statistical environment
and the ROCR tool. Graphical outputs were produced in JMP (SAS Institute, Inc., Cary, NC) and Excel
(Microsoft, Redmond, WA) software. Principal-component analyses (PCA) on seroreactive antigens were
conducted using JMP software to visually summarize signal intensity variance among the subject groups.
In parallel with the FOC method described above, a two-component mixture model was also used to
rank antigens. Reactivity against all 500 exon products at all time points for each subject was applied to
the mixture model using an R package (mixtools) for the R statistical environment (57). A subject-speciﬁc
reactivity cutoff point was deﬁned by the mean ⫹3 standard deviations for the low-reacting subpopulation distribution. An exon product with a reactivity above the cutoff point was identiﬁed as positive,
and the total number of positive responses per participant deﬁned the breadth of the proﬁle for that
subject. Antigens that induced a positive response in more than 25% of the total number of participants
were deﬁned as reactive at the population level. Reactive antigens were then ranked on the average
signal intensity.
Ethical considerations. The study was approved by the Institutional Review Board at the Johns
Hopkins Bloomberg School of Public Health, the Tropical Diseases Research Center Ethics Review
Committee in Ndola, Zambia, for studies in Choma District and Nchelenge District, Zambia, and the
Biomedical Research and Training Institute Institutional Review Board and the Medical Research Council
of Zimbabwe for studies in Mutasa District, Zimbabwe. Participants provided written informed consent
for themselves and their children.
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Accession number(s). The full content of the array (which is designated PfPv500) was deposited with
the Gene Expression Omnibus database (www.ncbi.nlm.nih.gov/geo/) under accession number
GPL18316, and the array data obtained in this study are publicly available at the PlasmoDB Plasmodium
Genomics Resource (plasmodb.org).
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